“Redefining the role of MERTK in anti-tumor immunity”

Carla Rothlin, PhD
Dorys McConnell Duberg Professor of Immunobiology and Pharmacology
Yale School of Medicine

Tuesday, May 4, 2021
4:00 – 5:00pm
Via Zoom – click for meeting link
By Telephone: 203-432-9666 – Meeting ID: 951 4009 7270 – Psw: HTI

CME credit: Text 22217 to 203-442-9435

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
The target audience for the HTI Seminar Series comprises attending faculty, clinical and basic scientists, community physicians, nurses, residents, fellows, and students.

NEEDS ASSESSMENT
The HTI Seminar Series seeks to review the scientific basis for choice of immunologically related therapeutic targets in various diseases, including organ-specific and systemic autoimmunity, allergy, transplant rejection, cancer, and infectious diseases. The goal is to help understand the rationale and mechanism underlying the major pharmacologic approaches for interventional immunology in current practice and review the data on the different therapeutic approaches in different specialties.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. Distinguish innate versus adaptive immune checkpoints.
2. Better appreciate the role of the receptor tyrosine kinase MERTK in the regulation of the innate immune response.
3. Understand the impact of disabling the function of MERTK in the immune response against different tumor types.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Carla Rothlin: Surface Oncology (Honorarium, Scientific Founder and SAB member); research grant from Mirati Pharmaceuticals.
Carrie Lucas: None
Ellen Foxman: None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

There is no corporate support for this activity

Seminar Host: Nikhil Joshi, PhD
Course Directors: Carrie Lucas, PhD and Ellen Foxman, MD, PhD

For additional information, please contact Allysia Matthews (allysia.matthews@yale.edu)